Sign in

3M Company MMM

Price 168.8 USD
as of 2026-09-03
50/100
No view
Quality66
Growth38
Balance-sheet strength37
Valuation43
Momentum60
Income57

Composite 50/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Balance-sheet strength ranks 37/100 — a moderate mark against it.

Case for

Quality ranks 66/100 — a moderate point in its favour. Momentum ranks 60/100 — a slight point in its favour. Income ranks 57/100 — a slight point in its favour.

Case against

Balance-sheet strength ranks 37/100 — a moderate mark against it. Growth ranks 38/100 — a slight mark against it. Valuation ranks 43/100 — a slight mark against it.

What the company does 3M Company operates through Safety and Industrial, Transportation and Electronics, and Consumer segments, supplying industrial abrasives, tapes, adhesives, respiratory protection, and electronics materials globally.

Key financials ROE 82%, ROA 9%, gross margin 39%, operating margin 20%, net margin 12%. Revenue growth 2%, EPS down 20%. Debt/Equity 4.38, net debt/EBITDA 1.21, current ratio 1.24. Dividend yield 1.8%, payout 35%.

Stock health Sideravia scores: Quality 66, Growth 41, Strength 38, Valuation 42, Momentum 66, Income 56. Piotroski F-Score 5/9. 3m momentum 14%, 12m 13%, RSI 45.

Price vs fair value The stock trades at a discount of 5% versus the analyst mean target of 183.26. - Simply Wall St notes MMM may be 11% below fair value on cash flow. - Zacks questions 3M’s ability to sustain margin momentum amid cost pressures. - Simply Wall St highlights a new CHRO appointment as a potential positive.

Looking forward Forward P/E 20.33 and PEG 0.34 suggest improved earnings visibility, but weak growth (1.5%) and high leverage remain headwinds. Margin recovery and execution on cost initiatives are key catalysts.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.